DBV Technologies S.A. Class Action Lawsuit - DBVT

(1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

In order to be eligible to join the DBVT class action lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

If you suffered a loss in during the relevant time frame or pursuant to the relevant offering(s), you have until March 18, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.